{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:46Z","timestamp":1786977886366,"version":"build-2736575974"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte\u2010colony stimulating factor [G\u2010CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re\u2010mobilization after a failed mobilization attempt with G\u2010CSF, and rescue or pre\u2010emptive mobilization in patients in whom mobilization with G\u2010CSF is likely to fail. Pre\u2010emptive use has the advantage that it avoids the need to re\u2010schedule the transplant procedure, with its attendant inconvenience, quality\u2010of\u2010life issues for the patient and cost of additional admissions to the transplant unit. UK experience from 2 major centers suggests that pre\u2010emptive plerixafor is associated with an incremental drug cost of less than \u00a32000 when averaged over all patients undergoing peripheral blood stem cell (PBSC) transplant. A CD34+ cell count of &lt;15 \u00b5l\n                    <jats:sup>\u22121<\/jats:sup>\n                    at the time of recovery after chemomobilization or after four days of G\u2010CSF treatment, or an apheresis yield of &lt;1 \u00d7 10\n                    <jats:sup>6<\/jats:sup>\n                    CD34+ cells\/kg on the first day of apheresis, could be used to predict the need for pre\u2010emptive plerixafor.\n                  <\/jats:p>","DOI":"10.1002\/jca.21563","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T07:58:48Z","timestamp":1497945528000},"page":"46-59","source":"Crossref","is-referenced-by-count":42,"title":["UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high\u2010dose chemoradiotherapy for patients with malignancy"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0057-7200","authenticated-orcid":false,"given":"Kenneth W.","family":"Douglas","sequence":"first","affiliation":[{"name":"Clinical Apheresis Unit Beatson West of Scotland Cancer Centre Glasgow United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gilleece","sequence":"additional","affiliation":[{"name":"Yorkshire Blood and Marrow Transplant Programme Leeds Teaching Hospitals Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hayden","sequence":"additional","affiliation":[{"name":"Haematology Department St James's Hospital Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hunter","sequence":"additional","affiliation":[{"name":"Haematology Department, Derriford Hospital Plymouth Hospitals NHS Trust Plymouth United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R. E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Haematology Western General Hospital Edinburgh United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kallmeyer","sequence":"additional","affiliation":[{"name":"Department of Haematology, Lincoln County Hospital United Lincolnshire Hospitals NHS Trust  Lincoln, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram K.","family":"Malladi","sequence":"additional","affiliation":[{"name":"Centre for Clinical Haematology University Hospitals Birmingham Birmingham United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[{"name":"Department of Haematology Heart of England NHS Foundation Trust Birmingham United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pawson","sequence":"additional","affiliation":[{"name":"Tissue Services and Cell Banking NHS Blood and Transplant  Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Haematology Belfast NHS Trust  Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[{"name":"Haematological Cancer Services King's College Hospital NHS Foundation Trust London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Southampton Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[{"name":"Bristol Haematology Unit University Hospitals Bristol  Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"Clinical Haematology Nottingham University Hospital Nottingham United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Snowden","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sheffield Teaching Hospitals Sheffield United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Department of Haematology Institut Catal\u00e1 d'Oncologia Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[{"name":"HSC Transplant Services, Department of Haematology Central Manchester University Hospitals Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Thomson","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology University College Hospitals London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Watts","sequence":"additional","affiliation":[{"name":"Wolfson Cellular Therapies Unit University College Hospitals London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Haematology Cardiff &amp; Vale University Health Board Cardiff United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1992.1.329"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.003"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.07.004"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.681042"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/11206040-000000000-00000"},{"key":"e_1_2_8_7_1","unstructured":"European Medicines Agency. Mozobil 20mg\/ml solution for injection. Summary of product characteristics.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001030\/WC500030686.pdf. Accessed February 20 2016."},{"key":"e_1_2_8_8_1","unstructured":"NHS England Clinical Commissioning Group for Blood & Bone Marrow Transplant. (2014) Clinical Commissioning Policy: Use of Plerixafor for Stem Cell Mobilisation (Update) \u2013 January 2014. Reference: NHS ENGLAND B04\/P\/2. On\u2013line reference.http:\/\/www.england.nhs.uk\/wp-content\/uploads\/2014\/02\/plerixafor-B04-p2.pdf. Accessed December 12 2014."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.013"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7209"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G\u2013CSF versus placebo and G\u2013CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio JF","year":"2009","journal-title":"Blood."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705908"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.54"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.93"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.128"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03349.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.119"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03136.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.78"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20239"},{"issue":"1","key":"e_1_2_8_21_1","first-page":"P1080","article-title":"(Abstract) A proactive approach to plerixafor use and subsequent apheresis can reduce failed autologous PBSC mobilization rates to virtually zero after two mobilization attempts: a single\u2013centre series of 40 consecutive PBSC mobilization episodes using plerixafor","volume":"46","author":"Douglas K","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"e_1_2_8_22_1","article-title":"Post\u2013licensing use of plerixafor for patients failing autologous PBSC mobilisation: a total single\u2013centre experience from a large UK cancer centre. (Abstract)","volume":"28","author":"Sinclair JE","year":"2013","journal-title":"J Clin Apher."},{"key":"e_1_2_8_23_1","unstructured":"Scottish Medicines Consortium. (2009) Plerixafor \u2013 advice following a full submission.http:\/\/www.scottishmedicines.org.uk\/files\/plerixafor__Mozobil__FINAL_December_2009.doc_for_website.pdf. Accessed December 12 2014."},{"issue":"1","key":"e_1_2_8_24_1","first-page":"S337","article-title":"(Abstract) Use of pre\u2010emptive plerixafor is successful in reducing mobilisation failure in myeloma patients undergoing PBSC mobilisation with cyclophosphamide and GCSF. (Abstract)","volume":"46","author":"Kallmeyer C","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.39"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12205"},{"key":"e_1_2_8_27_1","unstructured":"AABB (American Association of Blood Banks). Section 2: Collection of HPCs. In:Cellular Therapy:A Physician?s Handbook (1st Edition).SnyderEL HaleyNR eds. AABB Bethesda USA2004."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00774.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2012.066"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12606"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2008.04.002"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20191"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4614-1960-0_8","volume-title":"Novel Developments in Stem Cell Mobilization: Focus on CXCR4","author":"Douglas K.","year":"2012"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12813"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.802783"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.02.002"},{"issue":"1","key":"e_1_2_8_37_1","article-title":"(Abstract) Plerixafor is highly effective for the mobilization of autologous PBSC for transplant in children failing to mobilize by conventional means: international experience with 40 children from 19 centers","volume":"118","author":"Shenoy S","year":"2011","journal-title":"Blood."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.71"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03603.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/bmt.2011.185","article-title":"on behalf of the EBMT Autoimmune Working Party (ADWP) and Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune disease; updated guidelines of the European Group for blood and marrow transplantation","volume":"47","author":"Snowden JA","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.02.017"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12265"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.217"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.133"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.578312"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.196"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12198"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.82"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:51:24Z","timestamp":1695534684000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/jca.21563"],"URL":"https:\/\/doi.org\/10.1002\/jca.21563","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]}}}